Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

PHASE 1 trial: Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

At MD Anderson, TX (also Utah and Ohio)

Trial Link:

https://clinicaltrials.gov/study/NCT06096974?term=NCT06096974&rank=1

NOTE: All interventional trials involve risk.  So please consult with your oncology team as well as ask questions of the trial researchers.

Dec 2023:

“280Bio has dosed the first subject in a Phase I clinical study of oral pan-RAS inhibitor, TEB-17231 (YL-17231), to treat patients with advanced cancers harbouring mutations in KRAS, HRAS, or NRAS genes.

Investigational Cancer Therapeutics deputy chair and the trial lead investigator David Hong enrolled the first US subject at The University of Texas MD Anderson Cancer Center in Houston, Texas.”

https://www.clinicaltrialsarena.com/news/280bio-oral-ras-signalling-inhibitor-trial/

July 2023

280 Bio receives IND approval from the FDA for YL-17231

https://280bio.com/280-bio-receives-ind-approval-from-the-fda-for-yl-17231/?fbclid=IwY2xjawFgUhlleHRuA2FlbQIxMAABHRkbAnWRxwd9xrmo54NBjZ8Bu1ZDH-CwJnnaf8Wl1Finlq-staQI-mW5gw_aem_91FsjyfBOM4mG9Cc3iDI2w

Post in KRAS KICKERS’ Facebook group with additional information.

https://www.facebook.com/groups/kraskickers/posts/1043127167051002/